BONUS: Understanding and Managing Interstitial Lung Disease
Oct 17, 2024•6 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this bonus episode of Transforming Healthcare with electronRx, we explore the complexities of interstitial lung disease drawing inspiration from our recent blog.
This umbrella term used to describe a group of highly variable restrictive lung diseases, characterised by inflammation and pulmonary fibrosis.
Treatment options include:
- Corticosteroids: Pfizer, Novartis, GSK, Merck, Astrazeneca
- Bronchodilators: AstraZeneca, GSK
- Antifibrotics: Roche, Boehringer Ingelheim
- Immunosuppressants: Astrellas, Sanofi, Bristol-Myers Squibb, Novartis, Roche
To read the full blog visit electronrx.com
Brought to you by electronRx
Follow us on LinkedIn
For the best experience, listen in Metacast app for iOS or Android